These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

712 related items for PubMed ID: 25440022

  • 1. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
    Romei C, Tacito A, Molinaro E, Agate L, Bottici V, Viola D, Matrone A, Biagini A, Casella F, Ciampi R, Materazzi G, Miccoli P, Torregrossa L, Ugolini C, Basolo F, Vitti P, Elisei R.
    Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
    [Abstract] [Full Text] [Related]

  • 2. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A.
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [Abstract] [Full Text] [Related]

  • 3. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R, Bottici V, Cappagli V, Ramone T, Tacito A, Ciampi R, Romei C.
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [Abstract] [Full Text] [Related]

  • 4. [Clinical and genetic profile of patients with medullary thyroid cancer treated in the Cancer Centre--Institute of Oncology in Warsaw].
    Czetwertyńska M, Kozłowicz-Gudzińska I, Stachlewska-Nasfeter E, Sromek M, Skasko E, Paszko Z.
    Endokrynol Pol; 2006 Jun; 57(4):415-9. PubMed ID: 17006846
    [Abstract] [Full Text] [Related]

  • 5. Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades.
    Sarika HL, Papathoma A, Garofalaki M, Saltiki K, Pappa T, Pazaitou-Panayiotou K, Anastasiou E, Alevizaki M.
    Eur J Endocrinol; 2015 Apr; 172(4):501-9. PubMed ID: 25624014
    [Abstract] [Full Text] [Related]

  • 6. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E, Russo D, Giuffrida D, Zampa GA, Meringolo D, Arturi F, Chiodini I, Bianchi D, Attard M, Trischitta V, Bruno R, Giannasio P, Pontecorvi A, Filetti S.
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [Abstract] [Full Text] [Related]

  • 7. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
    Frank-Raue K, Rondot S, Schulze E, Raue F.
    Clin Lab; 2007 Jun; 53(5-6):273-82. PubMed ID: 17605401
    [Abstract] [Full Text] [Related]

  • 8. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M, Weinhüsel A, Niederle B, Haas OA.
    Int J Cancer; 1996 Aug 22; 69(4):312-6. PubMed ID: 8797874
    [Abstract] [Full Text] [Related]

  • 9. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
    Fitze G, Saeger HD, Roesner D, Schackert HK.
    Klin Padiatr; 2004 Aug 22; 216(5):270-6. PubMed ID: 15455293
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.
    Martins-Costa MC, Cunha LL, Lindsey SC, Camacho CP, Dotto RP, Furuzawa GK, Sousa MS, Kasamatsu TS, Kunii IS, Martins MM, Machado AL, Martins JR, Dias-da-Silva MR, Maciel RM.
    Endocr Relat Cancer; 2016 Dec 22; 23(12):909-920. PubMed ID: 27807060
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU.
    Cancer; 1995 Aug 01; 76(3):479-89. PubMed ID: 8625130
    [Abstract] [Full Text] [Related]

  • 14. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M, Ring A, Perinetti H, Elsner B, Iorcansky S, Barontini M.
    Cancer; 2002 Jan 15; 94(2):323-30. PubMed ID: 11900218
    [Abstract] [Full Text] [Related]

  • 15. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
    Wang J, Zhang B, Liu W, Zhang Y, Di X, Yang Y, Yan D.
    Fam Cancer; 2016 Jan 15; 15(1):99-104. PubMed ID: 26254625
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Multiple endocrine neoplasia type 2: 2007 update.
    Raue F, Frank-Raue K.
    Horm Res; 2007 Jan 15; 68 Suppl 5():101-4. PubMed ID: 18174721
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA.
    Clin Endocrinol (Oxf); 1995 Jul 15; 43(1):123-7. PubMed ID: 7641404
    [Abstract] [Full Text] [Related]

  • 20. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.
    Frank-Raue K, Rondot S, Raue F.
    Mol Cell Endocrinol; 2010 Jun 30; 322(1-2):2-7. PubMed ID: 20083156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.